Psychedelic drug developers rally after Trump orders FDA to expedite reviews
✨ AI Summary
🔊 جاري الاستماع
HealthInternationalPsychedelic drug developers rally after Trump orders FDA to expedite reviewsBy Reuters -Apr 21, 2026Shares of psychedelic drug developers rose on Monday after US President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic treatments and increased federal funding for their research. Shares of AtaiBeckley jumped 28% in morning trading, while Compass Pathways climbed 37%, Enveric BioSciences surged 140% and GH Research rose 24%. Definium Therapeutics gained 4% while US‑listed shares of Cybin, were up about 5%. The executive order, issued on Saturday, requires the US Food and Drug Administration to fast-track reviews of psychedelic compounds such as ibogaine, which is being studied to treat mental health conditions including post-traumatic stress disorder, depression and addiction. The order directs the agency to give Commissioner’s National Priority Vouchers to psychedelic drugs that have the “breakthrough therapy” tag, potentially cutting the review time to one to two months from the usual six to 10 months. Trump also said the government would allocate $50 million for federal research into ibogaine. Executives across the psychedelics industry welcomed the decision, saying clearer federal support could help accelerate research and responsible clinical use. Oppenheimer analysts called the development “a structural inflection for the U.S. psychedelics sector,” while Jefferies analyst Andrew Tsai called it the administration’s “official stamp of validation to the class (of drugs).” FDA Commissioner Marty Makary on Saturday said decisions on the drugs could come as soon as this summer. Ibogaine is derived from a shrub native to Africa and is classified as a Schedule I substance in the U.S., meaning it is considered to have no accepted medical use. According to RBC analyst Brian Abrahams, the signing of the executive order is “a substantial step towards diminishing regulatory risk in this...
